MetaCap

Immuneering Corporation Class A Company Profile

NASDAQ: IMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.38-0.07 (-2.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Immuneering at a glance

Immuneering Corporation Class A (NASDAQ: IMRX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Cambridge, MA. Immuneering is led by Dr. Benjamin J. Zeskind M.B.A., Ph.D. and employs about 65 people. The company's shares have traded publicly since 2021.

At a market capitalization of $218.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001790340, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Immuneering do?

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Immuneering Corporation Class A
Ticker
NASDAQ: IMRX
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Employees
65
Headquarters
245 Main Street, Cambridge, MA, United States
Phone
617 500 8080
IPO year
2021
Market cap
$218.90M
SEC CIK
0001790340
Latest annual report
10-K · Mar 6, 2026

Companies similar to Immuneering

IMRX peer companies
CompanyPrice% ChgMarket capCompare
RCKTRocket Pharmaceuticals Inc.1.95-7.58%$217.74Mvs IMRX
KROSKeros Therapeutics Inc.11.08-2.72%$217.44Mvs IMRX
PYXSPyxis Oncology Inc.1.81+7.74%$216.49Mvs IMRX
ENTAEnanta Pharmaceuticals Inc.7.62-4.51%$222.19Mvs IMRX
ARCTArcturus Therapeutics Holdings Inc.7.45-1.97%$214.73Mvs IMRX
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs IMRX
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs IMRX
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs IMRX

Related